EQL Pharma Dirección
Dirección controles de criterios 1/4
El CEO de EQL Pharma's es Axel Schorling, nombrado en Aug 2022, tiene una permanencia de 1.67 años. posee directamente un 0.88% de las acciones de la empresa, con un valor de SEK11.06M. La antigüedad media del equipo directivo y de la junta directiva es de 1.7 años y 5 años, respectivamente.
Información clave
Axel Schorling
Chief Executive Officer (CEO)
n/a
Compensación total
| Porcentaje del salario del CEO | n/a |
| Permanencia del CEO | 1.8yrs |
| Participación del CEO | 0.9% |
| Permanencia media de la dirección | 1.8yrs |
| Promedio de permanencia en la Junta Directiva | 5yrs |
Actualizaciones recientes de la dirección
We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair
Aug 10
How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?
Mar 11Recent updates
EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture
Feb 21The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested
Jun 28With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case
Apr 28EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors
Feb 24EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital
Dec 19Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?
Jun 29Is EQL Pharma (NGM:EQL) Using Too Much Debt?
Apr 29We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair
Aug 10EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns
Jun 07If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late
Apr 16How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?
Mar 11Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 21Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Feb 03What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation
Jan 16
Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?
Dec 28What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?
Dec 11EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment
Nov 22CEO
Axel Schorling (37 yo)
1.8yrs
Permanencia
Mr. Axel Schorling has been Independent Director at Gasporox AB (publ) since 2023. Mr. Schörling is President of EQL Pharma AB (publ) from August 15, 2022. He had been the Chief Operating Officer of EQL Ph...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder & Chairman | 18.3yrs | kr1.50m | sin datos | |
| President & CEO | 1.8yrs | sin datos | 0.88% SEK 11.3m | |
| Chief Financial Officer | 2.4yrs | sin datos | 0.047% SEK 601.4k | |
| Chief Operating Officer | 1.8yrs | sin datos | 0.052% SEK 665.8k | |
| Chief Commercial Officer | no data | sin datos | 0.88% SEK 11.2m | |
| Chief Business Development Officer | 1.2yrs | sin datos | sin datos |
1.8yrs
Permanencia media
49yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de EQL no se considera experimentado ( 1.7 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder & Chairman | 18.3yrs | kr1.50m | sin datos | |
| Non Independent Director | 9.3yrs | sin datos | sin datos | |
| Independent Director | 4.3yrs | sin datos | 0.0086% SEK 109.5k | |
| Independent Director | 5.8yrs | sin datos | 0.034% SEK 438.0k | |
| Independent Director | 3.3yrs | sin datos | 0.034% SEK 438.0k | |
| Independent Director | 3.3yrs | sin datos | sin datos |
5.0yrs
Permanencia media
57yo
Promedio de edad
Junta con experiencia: La junta directiva de EQL se considera experimentada (5 años de antigüedad promedio).